Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2059-2064

  Jiang, Hao ^a   Zhao, Pengjun ^b   Feng, Jianguo ^b   Su, Dan ^b   Ma, Shenglin ^c  

^a ZHEJIANG HOSPITAL   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Clonogenic cell survival; Gefitinib resistance; Paris saponin I; Radiosensitivity

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEFITINIB; PARIS SAPONIN I; PROTEIN BAX; PROTEIN BCL 2; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG ADENOCARCINOMA; MATHEMATICAL MODEL; MTT ASSAY; PROTEIN EXPRESSION; RADIOSENSITIVITY; SURVIVAL; UPREGULATION; WESTERN BLOTTING;

EID: 84898847661     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2020     Document Type: Article

References (27)

1. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
2. Workman P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51, 2004.
3. Kobayashi N, Toyooka S, Soh J, et al: The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 75: 161-166, 2012.
4. Jackman DM, Yeap BY, Sequist LV, et al: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908-3914, 2006.
5. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844, 2006.
6. Giaccone G: Clinical impact of novel treatment strategies. Oncogene 21: 6970-6981, 2002.
7. Grabley S and Thiericke R: Bioactive agents from natural sources: trends in discovery and application. Adv Biochem Eng Biotechnol 64: 101-154, 1999.
8. Wang Y, Zhang YJ, Gao WY and Yan LL: Anti-tumor constituents from Paris polyphylla var. yunnanensis. Zhongguo Zhong Yao Za Zhi 32: 1425-1428, 2007 (In Chinese).
9. Sun J, Liu BR, Hu WJ, et al: In vitro anticancer activity of aqueous extracts and ethanol extracts of fifteen traditional Chinese medicines on human digestive tumor cell lines. Phytother Res 21: 1102-1104, 2007.
10. Lee MS, Yuet-Wa JC, Kong SK, et al: Effects of polyphyllin D, a steroidal saponin in Paris polyphylla, in growth inhibition of human breast cancer cells and in xenograft. Cancer Biol Ther 4: 1248-1254, 2005.
11. Cheung JY, Ong RC, Suen YK, et al: Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2 cells. Cancer Lett 217: 203-211, 2005.
12. Siu FM, Ma DL, Cheung YW, et al: Proteomic and transcriptomic study on the action of a cytotoxic saponin (Polyphyllin D): induction of endoplasmic reticulum stress and mitochondria-mediated apoptotic pathways. Proteomics 8: 3105-3117, 2008.
13. Jiang H, Su D and Ma SL: The effect of Chonglou Saponin I on proliferation and apoptosis in lung adenocarcinoma cell line PC9. J Chinese Oncol 18: 166-169, 2012.
14. Hua YH, Ma SL, Fu ZF, et al: Effect of Polyphyllin I on radiosensitivity in nasopharyngeal carcinoma cell line CNE-2 in vitro. Chinese Archives of Traditional Chinese Medicine 29: 1387-1390, 2011 (In Chinese).
15. Xiao M, Dai X, He X, et al: Paris saponin I induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma SGC7901 cells. J Huazhong Univ Sci Technol Med Sci 31: 768-772, 2011.
16. Xiao X, Bai P, Bui Nguyen TM, et al: The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther 8: 1179-1188, 2009.
17. Yan LL, Zhang YJ, Gao WY, et al: In vitro and in vivo anticancer activity of steroid saponins of Paris polyphylla var. yunnanensis. Exp Oncol 31: 27-32, 2009.
18. Ji Y, Ma SL, Zhang YP, et al: Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Anticancer Drugs 20: 832-837, 2009.
19. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
20. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
21. Shroff EH, Snyder C and Chandel NS: Bcl-2 family members regulate anoxia-induced cell death. Antioxid Redox Signal 9: 1405-1409, 2007.
22. Reed JC, Miyashita T, Takayama S, et al: BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32, 1996.
23. Sedlak TW, Oltvai ZN, Yang E, et al: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92: 7834-7838, 1995.
24. Zha L, Qiao T, Yuan S, et al: Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells. Cancer Biother Radiopharm 25: 165-170, 2010.
25. Ma S, Tang J, Feng J, et al: Induction of p21 by p65 in p53 null cells treated with Doxorubicin. Biochim Biophys Acta 1783: 935-940, 2008.
26. Tang JJ, Shen C and Lu YJ: Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol Cell Biochem 291: 139-144, 2006.
27. Xiao GH, Beeser A, Chernoff J and Testa JR: p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 277: 883-886, 2002.